OCUL - Ocular Therapeutix Inc logo

Ocular Therapeutix Inc

OCUL

Ocular Therapeutix develops ophthalmic therapies using bioresorbable hydrogel technology. Its products include DEXTENZA for post-surgical ocular inflammation and AXPAXLI, in phase 3 for wet age-related macular degeneration and diabetic retinopathy.

โš•๏ธ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago โ†’$945today

Score Overview

1 Year
Score
Net Growth-13.35%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth0.45%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score1.9
Net Growth-44x
Net TrendNever
Net Income Consistencyโ€”
Rev Growth19.60%
Rev Trend80%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-4x
Net Trend20%
Net Income Consistency
Rev Growth27x
Rev Trend90%
Revenue Consistency
All Time
Score
Net Growth-8x
Net Trend17%
Net Income Consistency
Rev Growth67x
Rev Trend92%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Ocular Therapeutix Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. OCUL does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 6.50โ€”
1 Year2025-10-23
$ 11.44-43.18%
5 Years2021-10-22
$ 6.91-5.93%
10 Years2016-10-21
$ 6.88-5.52%
All Time2014-07-25
$ 13.15-50.57%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 52M-$ 301M$ 598M
2025$ 51M-$ 265M$ 737M
2024$ 63M-$ 193M$ 392M
2023$ 58M-$ 80M$ 195M
2022$ 51M-$ 71M$ 102M
2021$ 43M-$ 6M$ 164M
2020$ 17M-$ 155M$ 228M
2019$ 4M-$ 86M$ 54M
2018$ 1M-$ 57M$ 54M
2017$ 1M-$ 63M$ 41M
2016$ 1M-$ 44M$ 68M
2015$ 1M-$ 39M$ 105M
IPO2014$ 772K-$ 28M$ 74M
OCUL - Ocular Therapeutix Inc logo

Ocular Therapeutix Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 17M to $ 51M and net income went from -$ 155M to -$ 265M. Revenue increased in 4 of those 5 years; net income in 0.

Across Ocular Therapeutix Inc's full reported history, from 2014 to 2025, revenue grew from $ 772K to $ 51M and net income went from -$ 28M to -$ 265M. Revenue increased in 92% of the years measured; net income in 17%.

Ocular Therapeutix Inc currently holds a 5-year HDB Score of 1.9 out of 10. How the HDB Score is calculated.

Membership

Explore OCUL with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies